Shionogi & Co Ltd
TSE:4507
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 872.244
2 481.5958
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Shionogi & Co Ltd
Net Issuance of Common Stock
Shionogi & Co Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Net Issuance of Common Stock
-¥55.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Issuance of Common Stock
-¥1.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Issuance of Common Stock
-¥120.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-349%
|
CAGR 10-Years
-128%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Issuance of Common Stock
-¥20B
|
CAGR 3-Years
-2 616%
|
CAGR 5-Years
-625%
|
CAGR 10-Years
N/A
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Issuance of Common Stock
¥212m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-15%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Issuance of Common Stock
-¥7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
45%
|
CAGR 10-Years
19%
|
|
Shionogi & Co Ltd
Glance View
Shionogi & Co. Ltd., a prominent Japanese pharmaceutical company founded in 1878, has established itself as a key player in the global healthcare landscape through its unwavering commitment to innovation and patient-centric solutions. With a rich history that spans over a century, Shionogi has evolved from its roots in traditional medicine to a forward-thinking biopharmaceutical enterprise. It focuses on developing treatments for infectious diseases, pain management, and central nervous system disorders, leveraging its cutting-edge research capabilities and extensive pipeline of drugs. The company's strategic emphasis on transformative therapies not only aims to tackle prevalent health issues but also positions Shionogi for sustainable long-term growth in a competitive market. For investors, Shionogi offers a compelling story marked by strong fundamentals and a robust pipeline. As the company continues to target unmet medical needs, its recent advancements in antiviral treatments, particularly against COVID-19, demonstrate its agility in responding to global health crises. With a solid balance sheet and a history of steady revenue growth, Shionogi is well-equipped to navigate the evolving pharmaceutical landscape. Moreover, the company's commitment to research and development, which accounts for a significant portion of its budget, signals a proactive approach toward future innovations. For those looking to invest in a company with a legacy of excellence and a forward-looking vision, Shionogi & Co. Ltd. represents an enticing opportunity that combines stability with the promise of growth.
See Also
What is Shionogi & Co Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
-55.7B
JPY
Based on the financial report for Sep 30, 2024, Shionogi & Co Ltd's Net Issuance of Common Stock amounts to -55.7B JPY.
What is Shionogi & Co Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-15%
Over the last year, the Net Issuance of Common Stock growth was -22%. The average annual Net Issuance of Common Stock growth rates for Shionogi & Co Ltd have been -4% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
